Generate Biomedicines raises $370M Series B with a focus on protein-based drugs

Imogen Fitt

Published: December 6, 2021 In The News

18th November 2021 – Featured on Techcrunch.com – The drug development space is continuing to attract more and more investment. On Thursday, another major player, Generate Biomedicines, announced a $370 million Series B round.

Generate Biomedicines is touting a platform-based approach to drug development, but with its own spin: a focus on proteins.

Read full article here

You may also like

Insight

07 Mar 2019: AI in Healthcare, Healthcare IT, Medical Imaging, SPI Services

Focusing the Lens on Personalised Breast Imaging in Europe

25 years since it settled in Vienna, the European Conference of Radiology achieved record attendance as over 23k delegates made their way to Vienna. Breast imaging was one of the most talked about areas of radiology at the show, however it's a market traditionally slow to change in terms of technology.

Insight

26 May 2022: Diagnostics and Lifesciences, Digital Health, Healthcare IT

Why BoB LIS vendors might yet survive EHR’s invasion

EHR vendors are increasingly cannibalising clinical departmental IT administration, such as RIS, OIS, and CIS. Best of breed Laboratory Information Systems (BoB-LIS) are often viewed as the next departmental IT lamb headed for slaughter at the altar of the EHR. Is EHR-based LIS therefore a foregone conclusion?

Insight

22 Apr 2024: Diagnostics and Lifesciences

USCAP 2024 – Digital Pathology at the Tipping Point

22nd April 2024, USCAP’s annual meeting is one of the largest annual gatherings of pathologists globally, so when landing in Baltimore this year for the 113th event, we were eager to connect with industry leaders old and new to discuss their take on the ‘pulse’ of the conference and what it meant for the future of clinical pathology.

Generate Biomedicines raises $370M Series B with a focus on protein-based drugs

Share: